For its first fiscal quarter (ending March 31), Eli Lilly and Co (NYSE: LLY) has reported a 66% increase in E.P.S. from $1.49 a year ago to $2.48 in the current quarter. However, this result fell short of the consensus estimate of $3.39 by $-0.91. For the latest four quarters through March 31, E.P.S. were $6.81 versus $6.31 for the same period a year ago — an increase of 8%.
Recent Price Action
On 4/30/24, Eli Lilly and Co (NYSE: LLY) stock enjoyed a very large increase of 6.0%, closing at $781.10. Moreover, trading volume in this advance was exceptionally high at 266% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 6.8% during the last week.
Current PriceTarget Research Rating
LLY’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Eli Lilly has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Eli Lilly has a neutral Appreciation Score of 41 but a very high Power Rating of 89, leading to the Positive Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment